Small molecule · developed by Inventiva Pharma
Odiparcil is an oral tablet investigated in mucopolysaccharidosis VI.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03370653 | Phase 2 | Mucopolysaccharidosis VI | Completed | IVA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mucopolysaccharidosis VI
Updated Nov 15, 2026. Something wrong or missing? Report it on the IVA page.
See IVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IVA catalysts and pipeline →